Skip to main content

Advertisement

Fig. 4 | Virology Journal

Fig. 4

From: Interleukin-35 modulates the balance between viral specific CD4+CD25+CD127dim/- regulatory T cells and T helper 17 cells in chronic hepatitis B virus infection

Fig. 4

Influence of effective antiviral therapy to HBV core specific CD4+CD25+CD127dim/− regulatory T cells (Tregs), T helper 17 (Th17) cells, and responsiveness to interleukin (IL)-35 stimulation. Ten of chronic hepatitis B (CHB) patients received tenofovir disoproxil fumarate (TDF, 300 mg once daily). Peripheral blood mononuclear cells (PBMCs), CD4+ T cells, and CD4+CD25+CD127dim/− Tregs were isolated and purified three months post-therapy when reaching virological response. HBV core-specific CD4+CD25+CD127dim/− Tregs and CD4+IL-17+ Th17 cells prior to and post TDF therapy were investigated by flow cytometry, and IL-35 expression in the serum was measured by ELISA. a CD4+CD25+CD127dim/− Tregs percentage, (b) CD4+IL-17+ Th17 cells percentage, and (c) IL-35 expression did not change significantly in response to TDF-therapy. Purified CD4+ T cells from TDF-treated CHB patients were stimulated with HBc 18–17 peptide in the presence or absence of IL-35 for 12 h. HBV core-specific CD4+CD25+CD127dim/− Tregs and CD4+IL-17+ Th17 cells were investigated by flow cytometry. d CD4+CD25+CD127dim/− Tregs and (e) CD4+IL-17+ Th17 cells percentage in purified CD4+ T cells from TDF-treated patients did not change significantly in response to IL-35 stimulation. Purified CD4+CD25+CD127dim/− Tregs from TDF-treated CHB patients were stimulated with HBc 18–17 peptide in the presence or absence of IL-35 for 12 h. f CCR4+ cells and (g) CCR6+ cells in purified Tregs from TDF-treated patients did not change significantly in response to IL-35 stimulation. Individual level for each subject was presented, and comparisons were made using paired t tests

Back to article page